[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353597-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353597-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","supplementary-biomarker-testing-in-molecular-tumor-boards-increases-actionable-therapy-recommendations-a-prospective-real-world-study-of-658-patients","Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations - a prospective real-world study of 658 patients","","Molecular tumor boards (MTBs) are central for selecting therapies for patients with rare and advanced cancers. The study tests whether adding supplementary biomarkers beyond targeted DNA/RNA next-generation sequencing (NGS) increases actionable findings, focusing on HER2-low status, homologous recombination deficiency (HRD), and biomarkers supporting antibody–drug conjugate (ADC) use. Tumors were analyzed using the TSO500® panel and additional assays, while cases were discussed weekly and outcomes tracked systematically.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/supplementary-biomarker-testing-in-molecular-tumor-boards-increases-actionable-therapy-recommendations-a-prospective-real-world-study-of-658-patients/353597/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/supplementary-biomarker-testing-in-molecular-tumor-boards-increases-actionable-therapy-recommendations-a-prospective-real-world-study-of-658-patients/353597.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of supplementary biomarker testing in molecular tumor boards?","Question",{"text":63,"@type":64},"To determine whether integrating additional biomarkers beyond targeted DNA/RNA NGS increases the number of actionable therapy recommendations for patients with rare and advanced cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which additional biomarker assays were used alongside TSO500®?",{"text":68,"@type":64},"The study assessed HER2 using IHC and FISH, and evaluated ADC-related biomarkers via ADC IHC, plus MSI PCR, MMR IHC, PD-L1 IHC, and HRD analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about therapy recommendations and clinical benefit?",{"text":72,"@type":64},"Among 658 patients, 329 received therapy recommendations, including 182 based on supplementary biomarker analyses. Implementation rates were reported, and among evaluable patients the clinical benefit rate was 45.3%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353597,1790387472,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Scheiter etal. BMC Medicine (2026) 24:50 [https://doi.org/10.1186/s12916-026-04636-y](https://doi.org/10.1186/s12916-026-04636-y)  \nBMC Medicine  \n RESEARCH Open Access  \nSupplementary biomarker testing  \nin molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients  \nAlexander Scheiter1,2*† , Simon Mellin 1†, Felix Keil1 , Johannes Meier2,3 , Daniel Heudobler2,3,4, Christina Brummer4, Sabine Einhell4, Benjamin Zwicker4, Elena Wutzlhofer1, Frederik Hierl1, Sophie Klemm 1, Elena Lüftl 1, Tom Schneider 1, Markus Perl4, Margit Klier‑Richter1, Alexander Immel2,3, Till Kaltofen5 , Matthias Grube4, Elisabeth Bumes6, Stephan Seitz7, Christian Schulz8, Sebastian Haferkamp9, Konstantin Drexler9, Anja Troeger10, Felix Steger11, Sophie Schlosser‑Hupf12, Hauke Christian Tews12,  \nArne Kandulski 12 , Kristina Wohlfart5, Ramona Erber 1, Ines Schönbuchner13, Davor Lessel13,14,  \nMarco J. Schnabel 15, Anja M. Sedlmeier2,3,4, Monika Klinkhammer‑Schalke 16, Julia Maurer2,17, Diego F. Calvisi 1, Tobias Pukrop2,3,4,18, Ulrich Kaiser4,19, Daniela Hirsch 1,2, Wolfgang Dietmaier 1, Matthias Evert 1,  \nFlorian Lüke2,3,4,18† and Kirsten Utpatel 1,2†  \nAbstract  \nBackground Molecular tumor boards (MTBs) are essential for selecting therapies for patients with rare and advanced cancers. We hypothesized that integrating biomarkers beyond targeted DNA/RNA next‑generation sequencing (NGS) could increase actionable findings. Human epidermal growth factor receptor 2 (HER2)‑low status has emerged as a critical biomarker in breast cancer, with potential relevance across other tumor types. Homologous recombi‑ nation deficiency (HRD) is pivotal for the application of Poly(ADP‑Ribose)‑Polymerase (PARP) inhibitors in ovarian and breast cancer, although its role in other malignancies remains unclear. Antibody–drug conjugates (ADCs) are expanding precision oncology, with promising biomarkers like Trop‑2, Nectin‑4, and folate receptor alpha (FRα) show‑ ing potential across multiple tumor entities.  \nMethods Tumors were analyzed using the TSO500® panel, enabling tumor mutational burden (TMB) readout. HER2 status was assessed via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), alongside anti‑ body–drug conjugate (ADC) IHC, microsatellite instability (MSI) polymerase chain reaction (PCR), mismatch repair (MMR) IHC, programmed death‑ligand 1 (PD‑L1) IHC, and HRD analysis. Cases were discussed weekly, and outcomes were systematically tracked. Data analysis evaluated the benefit of additional biomarker assessments.  \n\n| †Alexander Scheiter and Simon Mellin are co‑first authors. |\n| --- |\n| †Florian Lüke and Kirsten Utpatel are co‑last authors. |\n\n*Correspondence:  \nAlexander Scheiter  \nAlexander.Scheiter@klinik.uni‑regensburg.de  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nScheiter etal. BMC Medicine (2026) 24:50 Page 2 of 26  \nResults Among 658 patients, 329 received therapy recommendations, 182 based on suppl","cbCaicPZznw30YI0","https://ap.wps.com/l/cbCaicPZznw30YI0","pdf",3824363,26,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"What is the main purpose of supplementary biomarker testing in molecular tumor boards?\",\"answer\":\"To determine whether integrating additional biomarkers beyond targeted DNA/RNA NGS increases the number of actionable therapy recommendations for patients with rare and advanced cancers.\"},{\"question\":\"Which additional biomarker assays were used alongside TSO500®?\",\"answer\":\"The study assessed HER2 using IHC and FISH, and evaluated ADC-related biomarkers via ADC IHC, plus MSI PCR, MMR IHC, PD-L1 IHC, and HRD analysis.\"},{\"question\":\"What did the results show about therapy recommendations and clinical benefit?\",\"answer\":\"Among 658 patients, 329 received therapy recommendations, including 182 based on supplementary biomarker analyses. Implementation rates were reported, and among evaluable patients the clinical benefit rate was 45.3%.\"}]","Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations - a prospective real-world study of 658 patients | PDF",1790106234,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0de0c4f5bfe613fb65cce599b347ebb.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce21b261a91e75a696ce9b8b68e40ae0.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f148fb9e3d0ad12290d1a4177d8a4bf.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60e5ccb01d6663d5eb627666df62c9a9.webp",980,1301]